Skip to main content

Table 1 Characteristics of patients used at the development of ERSPC RC3 (ERSPC section Rotterdam) and characteristics of patients collected at 5 different sites in Europe with information on the additional marker PHI

From: Improving prediction models with new markers: a comparison of updating strategies

Variable Measure or category ERSPC Rotterdam Paris Rennes Munster Hamburg Milan
   n = 3,616 n = 108 n = 188 n = 319 n = 182 n = 446
PSA (ng/ml) Median (25–75 percentile) 3.1 (2.8–3.6) 4.4 (3.5–5.6) 4.6 (3.5–5.8) 5.1 (4.1–6.4) 6.5 (4.4–9.6) 5.4 (4.2–7.0)
Prostate Volume 25 cc 739 (20 %) 22 (20 %) 48 (26 %) 78 (24 %) 83 (46 %) 271 (61 %)
  40 cc 1728 (49 %) 59 (55 %) 60 (32 %) 96 (30 %) 23 (13 %) 140 (31 %)
  60 cc 1149 (32 %) 27 (25 %) 80 (43 %) 145 (45 %) 76 (42 %) 35 (8 %)
Abnormal DRE Yes 1279 (35 %) 40 (37 %) 120 (64 %) 49 (15 %) 52 (29 %) 76 (17 %)
PHI Median (25–75 percentile) 45 (34–61) 68 (42–121) 45 (32–59) 40 (30–61) 47 (37–57)
Cancer Yes 885 (24 %) 62 (57 %) 107 (57 %) 184 (58 %) 100 (55 %) 187 (42 %)